Strategic Focus Targeted small molecule cannabinoid programs across Alzheimer’s, ocular, and dermatological indications, with a clear niche in rare cannabinoids via BayMedica — potential for partnerships or licensing in specialty pharma, neurology, and ophthalmology segments.

Executive Engagement Recent board appointments and advisory additions signal an active governance and expertise expansion, providing opening for high-touch BD outreach to collaborative ventures, strategic investors, and potential co-development opportunities.

Clinical & Academic Outreach Active participation in major conferences (AAIC) and addition of Alzheimer's experts to the Scientific Advisory Board indicate ongoing research momentum — ideal entry points for CRO collaborations, academic deals, and sponsored research or consulting opportunities.

Financial Footing Modest revenue range and anticipated funding events suggest opportunistic partnerships to accelerate development, including grant collaborations, milestone-based investments, or strategic partnerships to de-risk late-stage programs.

Digital & Channel Readiness Diverse tech stack including AWS, Drupal, Shopify, and marketing tools points to readiness for partner co-marketing, digital collaboration platforms, and potential channel sales models for niche cannabinoid-based products and research services.